Adaptive Biotechnologies
ADPT
176 hedge funds and large institutions have $538M invested in Adaptive Biotechnologies in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 69 increasing their positions, 45 reducing their positions, and 38 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 45
18% more capital invested
Capital invested by funds: $457M → $538M (+$80.7M)
2.61% more ownership
Funds ownership: 98.27% → 100.88% (+2.6%)
7% less funds holding
Funds holding: 190 → 176 (-14)
34% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 38
73% less call options, than puts
Call options by funds: $88K | Put options by funds: $323K
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$26.7M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$11.1M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$5.46M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$4.19M |
| 5 |
Jane Street
New York
|
+$2.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.39M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$5.77M |
| 3 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$5.42M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$4.36M |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$4M |
ADPT Hedge Fund Activity: Q2 2024 in Review
176 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q2 2024, worth a combined $538M — up 18% from $457M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of ADPT and 25 opened new positions — a net loss of 13 holders — while 45 trimmed existing stakes and 69 added.
The largest buyer was Millennium Management, adding an estimated $26.7M. The largest seller was Vanguard Group, cutting an estimated $8.39M.
- 176 institutional investors held Adaptive Biotechnologies (ADPT) as of Q2 2024, down from 190 in Q1 2024.
- Funds reported $538M of Adaptive Biotechnologies stock for Q2 2024, up 18% quarter-over-quarter.
- 25 funds opened new Adaptive Biotechnologies positions in Q2 2024 and 38 closed out, a net change of -13 holders.
- The largest Adaptive Biotechnologies buyer in Q2 2024 was Millennium Management, an estimated $26.7M added.
- The largest Adaptive Biotechnologies seller in Q2 2024 was Vanguard Group, an estimated $8.39M sold.
Based on aggregated 13F filings for Q2 2024.